北美药品辅助治疗(Mat)市场玩家,规模,份额,报告,价值,趋势

北美药物辅助治疗 (MAT) 市场，按类型（药物和疗法）、产品（丁丙诺啡和纳洛酮、纳曲酮、丁丙诺啡、美沙酮、纳洛酮、双硫仑和阿坎酸）、药物类型（仿制药和品牌药）、剂型（速释剂和缓释剂）、给药途径（口服、肠胃外和其他）、人群类型（成人和青少年）、最终用户（康复诊所、医院、专科中心、家庭护理和其他）分销渠道（医院药房、直接招标、零售药房、网上药房和其他）、行业趋势和预测到 2029 年

Medication-Assisted Treatment (MAT) Market

市场分析和见解

食品药品管理局(FDA)批准了三种临床药物:丁丙诺啡,美沙酮,和纳特莱克松. 药物辅助治疗(MAT)用于治疗酒精使用障碍、阿片依赖药物和阿片过量预防药物。酒精使用障碍(AUD)是一种医疗状况,其特点是,尽管在社会、职业或健康方面造成了不良后果,但停止酒精使用的能力仍然受损。 Acamprosate, disulfiram,和Naltrexone是最常见的用于治疗酒精使用障碍(AUD)的药物. 类阿片依赖药物,病人对类阿片的上瘾率上升。丁丙诺啡、美沙酮和纳特雷斯酮被用于治疗类阿片使用障碍以治疗海洛因、吗啡和可待因等短效类阿片以及半合成物质。类阿片像催产酮和氢可酮这些MAT药物在几个月,几年,甚至一生中都是安全的.

Medication-Assisted Treatment (MAT) Market

市场定义

药物辅助治疗(MAT)涉及使用药物,结合咨询和行为疗法,为治疗药物使用障碍提供完整的病人方法。对于类阿片过量预防药物,使用纳克酮来通过逆转过量的毒性影响来防止类阿片过量. 据世界卫生组织(卫生组织)和药物滥用和精神保健服务管理局(SAMHSA)称,纳克酮是许多被认为对运作良好的保健系统至关重要的药物之一。北美药物辅助治疗是支持性的,旨在降低症状的严重程度. 数据桥市场研究分析认为,从2022年到2029年,药物辅助(MAT)治疗市场将以9.7%的CAGR增长.

报表计量	细节
预测期	2022至2029年统计
基准年	2021
历史年代	2020年(2019-2014年可定制).
数量单位	收入(百万美元),定价(美元)
覆盖部分	按类型(药物和治疗)、产品(布普诺尔芬和纳洛克松、纳特雷克松、布普尔诺尔芬、美沙酮、纳洛克松、迪苏勒菲拉姆和阿坎普罗萨特)、药物类型(基因和品牌)、剂量表(立即释放和扩大释放)、管理路线(Oral、家长和其他)、人口类型(Adults和青少年)、终端用户(康复诊所、医院、专科中心、家庭护理等)分发渠道(医院药房、直接招标、零售药房、在线药房等)
涵盖国家	美国、加拿大和墨西哥
覆盖的市场玩家	Indivior PLC, Orexo US Inc (Orexo AB的子公司),美国恢复中心,阿尔克梅斯. 太阳制药工业有限公司,Purdue Pharma L.P.,Taj制药有限公司,Lannett,Hikma制药PLC,Pfize Inc.,Pinnacle治疗中心,美国毒瘾中心,Adamis制药公司,Glenmark制药公司Viatris Inc.,Mallinckrodt,Alvogen,Vistapharm, Inc.,Teva制药工业有限公司. Reddy's Laboratories Ltd. Amneal制药有限责任公司. 泰坦制药股份有限公司.

北美药品辅助治疗市场动态

司机

酒精发病率上升使用失调症,阿片使用失调症

酒精使用障碍(AUD)是一种医疗状况,其特点是,尽管在社会、职业或健康方面产生了不利后果,但停止或控制酒精使用的能力仍然受损。它包括一些人所说的酗酒、酗酒和酗酒等条件。药物辅助治疗(MAT)是指结合咨询和行为疗法使用药物,提供"全病人"治疗药物使用障碍的方法. MAT中使用的药物由食品和药品管理局(FDA)批准,MAT方案由临床驱动并量身定制以满足每个病人的需求.

比如说,

在2022年,世界卫生组织(卫生组织)欧洲区域的数据指出,酒精紊乱每年造成100万人死亡。

由于这些公司不断从事研究和开发活动,了解酗酒和类阿片使用失调的发生率将有助于找到新的解决办法,并将有助于与美国、欧洲和亚太区域等国家的市场参与者开展更多的合作并建立伙伴关系。这表明与研究和开发有关的投资有所增加,用于启动药物辅助治疗的非专利药品,预计这将促进市场增长。

政府为药品辅助治疗提供的资金

尽管治疗类阿片使用和酒精紊乱的药效已经得到确认,但人们注意到,专科治疗方案对实施戒毒治疗药物的限制。需要特别注意资金、组织结构和劳动力资源的具体来源,进行长期投资,使付款与未来可能的受益者保持一致。

比如说,

2021年1月,根据联邦政府登记册,农村社区发展倡议赠款(RCDI)向中介组织提供资金和技术援助,帮助满足符合条件的农村地区社区的需求。

政府的资助将带来患者的安全并节省费用. 此外,医院和保健机构将通过与政府组织合作,以更低的价格管理这种治疗。因此,研究与发展活动的进展以及政府提供的资金可望推动市场增长。

机会

保健支出上升

此外,研究和发展活动的增加以及政府和私营组织投资的增加将增加市场增长率的新机会。

比如说,

2021年2月,根据"保健价格指数"(HCPI),美国保健预算总额增加了3.4%。增长的增长表明,联邦政府的支出在上一年大幅减少,从2020年的2.87亿美元减少到2021年的1.7亿美元。

不断增加的保健支出也有利于保健部门的进一步发展和增长。此外,人口可支配收入的增加也是一个有利因素。预计上述情况将为药物辅助治疗市场创造有利可图的机会。

限制/挑战

药物治疗中使用的药物的副作用

药物辅助治疗(MAT)涉及使用经咨询和行为疗法整理的药物,作为综合治疗战略的一部分,提供"全患者"方法. 因此,目前的高成本预计将呈现出下降趋势。 MAT对于治疗酒精和类阿片使用障碍最为有效. 然而,有报告指出了具体的副作用。

比如说,

美沙酮和丁丙诺啡等同类药物在化学上与类阿片相似,因此其副作用也可以相类似. 这些可能包括便秘、昏睡和眩晕。有些人可能会受到更严重的副作用

所报告的不良并发症会使阿片类药物依赖性药物的销售下降,从而会限制药物的销售。此外,这将影响参与这一市场的制造商的可靠性,因此,预期会限制市场增长。

药品辅助治疗(MAT)市场报告详细介绍了近期新发展,贸易监管,进出口分析,生产分析,价值链优化,市场份额,国内和地方市场主体影响等情况,分析了新兴收入领域,市场监管变化,战略性市场增长分析,市场规模,类别市场增长,应用优势和支配地位,产品审批,产品推出,地域扩张,市场技术创新等方面的机会. 为了获得更多关于医疗辅助(MAT)治疗市场联系数据桥市场研究的信息,我们团队将帮助你做出知情的市场决定,实现市场增长.

影响药品辅助治疗市场

在这一流行病期间,药物辅助治疗显著地降低了COVID-19患者的死亡率和发病率。需要进一步进行大规模研究,以核准这些结果。应对COVID-19感染药物辅助治疗规程进行界定,以取得最佳临床结果。在Covid-19药物治疗期间,针对类阿片使用紊乱症的服务进行了临床试验,这是解决类阿片危机的关键所在,而COVID-19对提供类阿片使用紊乱症产生了重大影响。

最近的发展

2021年4月,阿达米斯制药公司与USWM公司宣布推出并供应高剂量的ZIMHI可注射纳克酮产品来帮助对抗类阿片过量死亡. 预计启动将增加产品部门收入,这将促进市场增长,ZIMHI将以折扣率提供给第一反应者和社区保健组织

北美药物辅助治疗市场范围

药物辅助(MAT)治疗市场按8个部分划分:类型、产品、药物类型、剂量形式、管理路线、人口类型、最终用户和分配渠道。这些部门的增长将有助于你分析这些行业中增长不足的部分,并为用户提供宝贵的市场概况和市场见解,帮助他们作出确定核心市场应用的战略决定。

类型

药品
治疗

根据类型,北美药物辅助治疗市场分为药物和治疗。

产品

丁诺啡和纳洛克酮
纳特雷克松
布普罗诺芬
美沙酮
纳洛克酮
迪苏菲拉姆
营地

在产品的基础上,北美药物辅助治疗市场被分解成丁丙诺啡和纳克酮,纳克勒克酮,丁丙诺啡,美沙酮,纳克勒克酮,去甲磺酰胺和甘油.

药物类型

常规
品牌

根据药物类型,北美药物辅助治疗(MAT)市场被分割成通用药并被打上品牌.

剂量表单

立即释放
扩展发行

根据剂量表,北美药物辅助治疗(MAT)市场被分割为即时释放和延长释放.

行政路线

口头
家长
其他人员

根据管理途径,北美药物辅助治疗(MAT)市场被分为口服,亲服等.

人口类型

成年人
青少年

根据人口类型,北美药物辅助治疗市场分为成人和青少年两个部分。

结束用户

康复诊所
医院
专业中心
家庭护理
其他人员

在最终用户的基础上,北美药物辅助治疗市场分为康复诊所、医院、专科中心、家庭护理等。

分发频道

医院药房
直接招标
零售药店
在线药店
其他人员

Medication-Assisted Treatment (MAT) Market

根据分销渠道,北美药物辅助治疗市场分为医院药房,直接招标,零售药房,在线药房等.

药品辅助治疗市场区域分析/见解

对北美药物辅助治疗(MAT)市场进行分析,并按区域、产品类型、类型、应用、工作流程、最终用户和分销渠道提供市场规模的见解和趋势。

药物援助治疗市场报告所涵盖的国家是美国、加拿大和墨西哥。

由于对阿片类药物的依赖、保健开支和制药公司的增加,预计美国将主导市场。

报告的国家部分还提供了影响当前和未来市场趋势的个别市场影响因素和国内监管变化。新的销售、替代销售、国家人口统计、疾病流行病学和进出口关税等数据点是用来预测个别国家市场情况的一些主要指针。此外,在提供国家数据的预测分析的同时,还考虑到北美品牌的存在和可得性,以及它们因来自当地和国内品牌的激烈竞争而面临的挑战和销售渠道的影响。

竞争性景观和药品辅助治疗市场共享分析

北美药物辅助治疗(MAT)市场竞争环境提供了竞争者的详细情况。详细情况包括公司概况、公司财务、创收、市场潜力、研发投资、新市场举措、北美的存在、生产地点和设施、生产能力、公司优势和弱点、产品推出、产品宽度和广度、应用优势。上述数据点只涉及公司对药物援助治疗市场的重视。

在药物辅助(MAT)治疗市场经营的一些主要角色有:Indivior PLC,Orexo US Inc(Orexo AB的子公司),美国复苏中心,阿尔克梅斯. 太阳制药工业有限公司、Purdue Pharma L.P.、Taj制药有限公司、Lannett、Hikma制药公司、Pfize公司、Pinnacle治疗中心、美国成瘾中心、Adamis制药公司、Glenmark制药公司、Viatris公司、Mallinckrodt、Alvogen、VistaPharm公司、Amneal制药有限责任公司。泰坦制药股份有限公司.

SKU-68670

在线获取全球首个市场情报云平台的报告访问权限

点击图片放大

交互式数据分析仪表板
用于发现高增长潜力机会的公司分析仪表板
研究分析师支持（定制与咨询）
带有交互式仪表板的竞争对手分析
最新新闻、更新与趋势分析
利用基准分析的强大功能，实现全面的竞争对手跟踪

申请演示

表格列表

TABLE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 2 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 3 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 4 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 5 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 6 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 7 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 8 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 10 NORTH AMERICA BUPRENORPHINE AND NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 11 NORTH AMERICA NALTREXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 12 NORTH AMERICA BUPRENORPHINE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 13 NORTH AMERICA METHADONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 14 NORTH AMERICA NALOXONE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 15 NORTH AMERICA DISULFIRAM IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 16 NORTH AMERICA ACAMPROSATE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 18 NORTH AMERICA GENERICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 19 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 20 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 22 NORTH AMERICA IMMEDIATE RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 23 NORTH AMERICA EXTENDED RELEASE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 25 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 26 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 27 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 28 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 29 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 31 NORTH AMERICA ADULTS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 32 NORTH AMERICA TEENAGE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 34 NORTH AMERICA REHABILITATION CLINICS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 35 NORTH AMERICA HOSPITALS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 36 NORTH AMERICA SPECIALTY CENTERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 37 NORTH AMERICA HOMECARE IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 38 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 40 NORTH AMERICA HOSPITAL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 41 NORTH AMERICA DIRECT TENDER IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 42 NORTH AMERICA RETAIL PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 43 NORTH AMERICA ONLINE PHARMACY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 44 NORTH AMERICA OTHERS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY REGION, 2020-2029 (USD MILLION)

TABLE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY COUNTRY, 2020-2029 (USD MILLION)

TABLE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 47 NORTH AMERICA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 48 NORTH AMERICA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 49 NORTH AMERICA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 50 NORTH AMERICA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 51 NORTH AMERICA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 54 NORTH AMERICA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 55 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 56 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 57 NORTH AMERICA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 58 NORTH AMERICA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 59 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 60 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 61 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 62 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 63 U.S. MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 64 U.S. OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 65 U.S. ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 66 U.S. OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 67 U.S. THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 68 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 69 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 70 U.S. BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 71 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 72 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 73 U.S. ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 74 U.S. PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 75 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 76 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 77 U.S. MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 78 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 79 CANADA MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 80 CANADA OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 81 CANADA ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 82 CANADA OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 83 CANADA THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 84 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 85 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 86 CANADA BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 87 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 88 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 89 CANADA ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 90 CANADA PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 91 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 92 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 93 CANADA MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

TABLE 94 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 95 MEXICO MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 96 MEXICO OPIOID DEPENDENCY MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 97 MEXICO ALCOHOL USE DISORDER MEDICATIONS IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 98 MEXICO OPIOID OVERDOSE PREVENTION MEDICATION IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 99 MEXICO THERAPY IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY TYPE, 2020-2029 (USD MILLION)

TABLE 100 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY PRODUCTS, 2020-2029 (USD MILLION)

TABLE 101 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 102 MEXICO BRANDED IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DRUG TYPE, 2020-2029 (USD MILLION)

TABLE 103 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DOSAGE FORM, 2020-2029 (USD MILLION)

TABLE 104 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 105 MEXICO ORAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 106 MEXICO PARENTERAL IN MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY ROUTE OF ADMINISTRATION, 2020-2029 (USD MILLION)

TABLE 107 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY POPULATION TYPE, 2020-2029 (USD MILLION)

TABLE 108 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY END USER, 2020-2029 (USD MILLION)

TABLE 109 MEXICO MEDICATION-ASSISTED TREATMENT (MAT) MARKET, BY DISTRIBUTION CHANNEL, 2020-2029 (USD MILLION)

图片列表

FIGURE 1 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET : SEGMENTATION

FIGURE 2 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DATA TRIANGULATION

FIGURE 3 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DROC ANALYSIS

FIGURE 4 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: NORTH AMERICA VS REGIONAL MARKET ANALYSIS

FIGURE 5 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: DBMR POSITION GRID

FIGURE 8 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: VENDOR SHARE ANALYSIS

FIGURE 9 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: END USER COVERAGE GRID

FIGURE 10 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SEGMENTATION

FIGURE 11 NORTH AMERICA IS ANTICIPATED TO DOMINATE THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET AND ASIA-PACIFIC IS ESTIMATED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2022 TO 2029

FIGURE 12 INCREASED INCIDENCE OF ALCOHOL USE DISORDERS AND RISE IN PRODUCT APPROVALS IS EXPECTED TO DRIVE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 TO 2029

FIGURE 13 TYPE SEGMENT IS EXPECTED TO HAVE THE LARGEST SHARE OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET FROM 2022 & 2029

FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET

FIGURE 15 INCIDENCE OF ALCOHOL CONSUMPTION IN 2019

FIGURE 16 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2021

FIGURE 17 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, 2022-2029 (USD MILLION)

FIGURE 18 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, CAGR (2022-2029)

FIGURE 19 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE, LIFELINE CURVE

FIGURE 20 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2021

FIGURE 21 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, 2022-2029 (USD MILLION)

FIGURE 22 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, CAGR (2022-2029)

FIGURE 23 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY PRODUCTS, LIFELINE CURVE

FIGURE 24 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2021

FIGURE 25 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, 2022-2029 (USD MILLION)

FIGURE 26 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, CAGR (2022-2029)

FIGURE 27 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DRUG TYPE, LIFELINE CURVE

FIGURE 28 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2021

FIGURE 29 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, 2022-2029 (USD MILLION)

FIGURE 30 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, CAGR (2022-2029)

FIGURE 31 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DOSAGE FORM, LIFELINE CURVE

FIGURE 32 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2021

FIGURE 33 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, 2022-2029 (USD MILLION)

FIGURE 34 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2022-2029)

FIGURE 35 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 36 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2021

FIGURE 37 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, 2022-2029 (USD MILLION)

FIGURE 38 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, CAGR (2022-2029)

FIGURE 39 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY POPULATION TYPE, LIFELINE CURVE

FIGURE 40 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2021

FIGURE 41 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, 2022-2029 (USD MILLION)

FIGURE 42 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, CAGR (2022-2029)

FIGURE 43 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY END USER, LIFELINE CURVE

FIGURE 44 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2021

FIGURE 45 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, 2022-2029 (USD MILLION)

FIGURE 46 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, CAGR (2022-2029)

FIGURE 47 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 48 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: SNAPSHOT (2021)

FIGURE 49 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021)

FIGURE 50 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2022 & 2029)

FIGURE 51 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY COUNTRY (2021 & 2029)

FIGURE 52 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: BY TYPE (2022-2029)

FIGURE 53 NORTH AMERICA MEDICATION-ASSISTED TREATMENT (MAT) MARKET: COMPANY SHARE 2021 (%)

查看详细信息

研究方法

数据收集和基准年分析是使用具有大样本量的数据收集模块完成的。该阶段包括通过各种来源和策略获取市场信息或相关数据。它包括提前检查和规划从过去获得的所有数据。它同样包括检查不同信息源中出现的信息不一致。使用市场统计和连贯模型分析和估计市场数据。此外，市场份额分析和关键趋势分析是市场报告中的主要成功因素。要了解更多信息，请请求分析师致电或下拉您的询问。

DBMR 研究团队使用的关键研究方法是数据三角测量，其中包括数据挖掘、数据变量对市场影响的分析和主要（行业专家）验证。数据模型包括供应商定位网格、市场时间线分析、市场概览和指南、公司定位网格、专利分析、定价分析、公司市场份额分析、测量标准、全球与区域和供应商份额分析。要了解有关研究方法的更多信息，请向我们的行业专家咨询。

可定制

Data Bridge Market Research 是高级形成性研究领域的领导者。我们为向现有和新客户提供符合其目标的数据和分析而感到自豪。报告可定制，包括目标品牌的价格趋势分析、了解其他国家的市场（索取国家列表）、临床试验结果数据、文献综述、翻新市场和产品基础分析。目标竞争对手的市场分析可以从基于技术的分析到市场组合策略进行分析。我们可以按照您所需的格式和数据样式添加您需要的任意数量的竞争对手数据。我们的分析师团队还可以为您提供原始 Excel 文件数据透视表（事实手册）中的数据，或者可以帮助您根据报告中的数据集创建演示文稿。